KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Arbutus Biopharma (ABUS) over the last 16 years, with Q3 2025 value amounting to $227000.0.

  • Arbutus Biopharma's Gains from Investment Securities fell 3401.16% to $227000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 18243.24%. This contributed to the annual value of $2.6 million for FY2024, which is 370434.78% up from last year.
  • As of Q3 2025, Arbutus Biopharma's Gains from Investment Securities stood at $227000.0, which was down 3401.16% from $300000.0 recorded in Q2 2025.
  • Arbutus Biopharma's Gains from Investment Securities' 5-year high stood at $1.9 million during Q4 2024, with a 5-year trough of -$636000.0 in Q2 2023.
  • In the last 5 years, Arbutus Biopharma's Gains from Investment Securities had a median value of $227000.0 in 2023 and averaged $401368.4.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first surged by 73367.88% in 2022, then plummeted by 40576.92% in 2023.
  • Over the past 5 years, Arbutus Biopharma's Gains from Investment Securities (Quarter) stood at $193000.0 in 2021, then surged by 733.68% to $1.6 million in 2022, then crashed by 85.89% to $227000.0 in 2023, then skyrocketed by 732.6% to $1.9 million in 2024, then crashed by 87.99% to $227000.0 in 2025.
  • Its Gains from Investment Securities stands at $227000.0 for Q3 2025, versus $300000.0 for Q2 2025 and $300000.0 for Q1 2025.